NAVEGA THERAPEUTICS, INC.
Gene therapy using selective NaV1.7 repression to treat chronic pain
- Sector
- Biotech
- Headquarters
- La Jolla, CA
- Latest Form D
- $1.3M, Jan 2026
- Total capital
- $7M
- Federal grants
- $5.7M
- 9 awards · 2019–2025
- Rank in peer group#125 of 514
- Private capital raised
- $1.3M
- 1 Form D · last Jan 2026
- 9 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 11 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$1.3M
- Federal grantHealth and Human S · Phase I · Reformulating NT-Z001 and its delivery route to treat rheumatoid arthritis$297K
- Federal grantHealth and Human S · Phase II · Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$1.3M
- Federal grantHealth and Human S · Phase II · Supplement to Promote Diversity, Inclusion, and Career Development of a Female Scientist$134K
- Federal grantHealth and Human S · Phase I · Optimization of a Gene Therapy for Chronic Pain in Human DRGs$275K
- Federal grantHealth and Human S · Phase II · Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$2.2M
- Federal grantHealth and Human S · Phase I · Supplement to Promote Diversity and Inclusion, Female Scientist$95K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase I · Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$288K
- Federal grantHealth and Human S · Phase I · Supplement to Promote Diversity and Inclusion, Female Scientist$624K
- Federal grantHealth and Human S · Phase I · Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain$529K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
76months
from NAVEGA THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Sep 2019
- Health and Human S · $529K
- First Form D · Jan 2026
- $1.3M · 1st Form D
- Awards before first raise
- 9 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#125 · top 24%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Ana MorenoResearcherExecutive Officer, DirectorLinked by $899K in grants as PI
- Fernando AlemanExecutive Officer, DirectorNamed in SEC Form D filings
- Randy SocolExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 11- PendingCompositions And Methods For Epigenetic Modulation Of NAV1.7USPTOApplication 18907287
- PendingCompositions And Methods For Reducing Pain And Inflammation Through Epigenetic ModulationUSPTOApplication 18754071
- PendingEpigenetic Gene Regulation To Treat Neurological Diseases And PainUSPTOApplication 18274978
Show all 11 patent records
- Compositions And Methods For Epigenetic Modulation Of NAV1.7Apr 10, 2025 · Application 18907287Pending
- Compositions And Methods For Reducing Pain And Inflammation Through Epigenetic ModulationFeb 20, 2025 · Application 18754071Pending
- Epigenetic Gene Regulation To Treat Neurological Diseases And PainNov 7, 2024 · Application 18274978Pending
- Compositions And Methods For Reducing Pain And Inflammation Through Epigenetic ModulationApplication PCTUS2024035482Pending
- Compositions And Methods For Epigenetic Modulation Of NAV1.7Application 63543029Pending
- Compositions And Methods For Epigenetic Modulation Of NAV1.7Application 63588260Pending
- Compositions And Methods For Reducing Pain And Inflammation Through Epigenetic ModulationApplication 63523353Pending
- Epigenetic Gene Regulation To Treat Neurological Diseases And PainApplication PCTUS2022014601Pending
- Epigenetic Gene Regulation To Treat Neurological Diseases And PainApplication 63144408Pending
- Compositions And Methods For Epigenetic Modulation Of NAV1.7Application PCTUS2024050105Pending
- Compositions And Methods For Epigenetic Modulation Of NAV1.7Application 63692441Pending
Related companies, and why
- XYLOCOR THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- KHLORIS BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Phenovista Biosciences LLCSimilar federal contract value in Biotech · null in contracts
- ANTIDOTE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Koutif Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
- CERRX, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .